ArticleIranian journal of pharmaceutical research : IJPR2018
Aptamer-based Targeted Delivery of miRNA let-7d to Gastric Cancer Cells as a Novel Anti-Tumor Therapeutic Agent.
Article in Iranian journal of pharmaceutical research : IJPR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Enhancing the intracellular delivery of antisense oligonucleotides (ASO) : a comparative study of aptamer, vitamin E, and cholesterol ASO conjugates.RSC advances · 2025Article
- Aptamer-based applications in delivering cancer gene therapies and beyond: state of the art and the missing links to clinical translation.Advanced drug delivery reviews · 2025Review
- Advances in Expression Regulation, Molecular Targeting Mechanisms, and Therapeutic Applications of the Let-7 MicroRNA Family in Gastric Cancer.Oncology research · 2025Review
- Review
- Selective Delivery to Cardiac Muscle Cells Using Cell-Specific Aptamers.Pharmaceuticals (Basel, Switzerland) · 2023Article
- The fluorescence regulation of a tri-functional oligonucleotide probe HEX-OND in detecting Pb(II), cysteine, and K(I) based on two G-quadruplex forms.Analytical and bioanalytical chemistry · 2023Article
- MicroRNA as a Diagnostic Tool, Therapeutic Target and Potential Biomarker in Cutaneous Malignant Melanoma Detection-Narrative Review.International journal of molecular sciences · 2023Review
- Molecular Targets of Aptamers in Gastrointestinal Cancers: Cancer Detection, Therapeutic Applications, and Associated Mechanisms.Journal of Cancer · 2023Review
- Aptamer‑based therapy for targeting key mediators of cancer metastasis (Review).International journal of oncology · 2022Review
- miRNA therapeutics in precision oncology: a natural premium to nurture.Exploration of targeted anti-tumor therapy · 2022Review
- Hsa-let-7d-5p Promotes Gastric Cancer Progression by Targeting PRDM5.Journal of oncology · 2022Article
- Engineered Aptamers for Enhanced COVID-19 Theranostics.Cellular and molecular bioengineering · 2021Review
- Challenges identifying efficacious miRNA therapeutics for cancer.Expert opinion on drug discovery · 2020Article
- G-Quadruplex-Forming Aptamers-Characteristics, Applications, and Perspectives.Molecules (Basel, Switzerland) · 2019Review
- Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib.Asian Pacific journal of cancer prevention : APJCP · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
miRNAs as one of the potential therapeutic agents have been recently considered for cancer treatment. AS1411 (aptNCL) is a DNA aptamer specifically binding to nucleolin protein on the cancer cell surface with antiproliferative effect. The aim of the study was to develop a conjugate consisting of aptNCL (as targeted delivery of therapeutic agent) and miRNA let-7d (as a tumor suppressor) using two different linking methods and also to evaluate the potential effect of the conjugates on the proliferation of gastric cancer (MKN-45) cell line compared to negative control cell line of human dermal fibroblast (HDF). Conjugation was performed covalently by SM (PEG)
Indexed as
Identifiers
30568710PMC6269583W2897058813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.